India has the second-highest number of people with type 2 diabetes after China and rising obesity rates, making it a critical ...

Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar ...

New obesity treatments, including ‘oral Mounjaro’ and ‘high-dose Wegovy,’ are scheduled to be launched next year. The U.S.

Ozempic, a once-weekly injectable approved by the US Food and Drug Administration in 2017 for type 2 diabetes, has become a ...

After Novo Nordisk sought an injunction alleging patent infringement, the Court found Dr. Reddy’s challenge to the patent ...

Two large trials of Novo Nordisk's semaglutide showed no cognitive benefits for early Alzheimer's patients, dashing hopes for the drug as a potential treatment.

Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people ...

Novo Nordisk says it still thinks GLP-1 drugs could be a promising treatment for Alzheimer’s, despite two disappointing ...

In this week’s edition of InnovationRx, we look at the Forbes 30 Under 30 Healthcare list, the coming barriers to getting ...

The CMS has just announced a new list of medicines selected for this program that includes Novo Nordisk's Wegovy, Ozempic, ...

While the TrumpRx deals only cover Lilly and Novo for now, the agreements are good for any cardiometabolic biotechs waiting ...